Joint with: Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk
Chronic Kidney Disease: Emerging Mechanisms, Consequences and Targeted Treatments

Apr 12–15, 2026 | Fairmont Hotel Vancouver, Vancouver, BC, Canada
Scientific Organizers: Matthias Kretzler, Hiddo Lambers Heerspink, Olga G. Troyanskaya and Maria Chiara Magnone

  In Person
  On Demand

Apr 12–15, 2026 | Fairmont Hotel Vancouver, Vancouver, BC, Canada
Scientific Organizers: Matthias Kretzler, Hiddo Lambers Heerspink, Olga G. Troyanskaya and Maria Chiara Magnone

Available Formats:   = In Person     = On Demand
Sunday, April 12, 2026
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Monday, April 13, 2026
Breakfast
7:30–8:30 AM
Welcome and Keynote Address
8:30–10:00 AM
Griffin P. Rodgers †, National Institute of Diabetes, Digestive and Kidney Diseases
Building the Village of Precision Medicine for Kidney Disease: NIDDK Vision for CKD in 2026
Coffee Break
10:00–10:20 AM
CKD Function and Failure; From Models to Man
10:20–11:45 AM
Melissa Hallow †, University of Georgia
Modelling Kidney Function: What Renal Physiology Teaches us in 2025 for CKD: Lessons Learned from Modeling Endothelin Function in CKD Trials
Samira Musah †, Duke University
Kidney Tissue Bioengineering for Patient Level Precision Medicine
Jonathan Himmelfarb †, Mount Sinai School of Medicine
Ex vivo Organ Cross Talk: Liver-Kidney System Defines Molecular Cross Talk in Toxin Induced CKD
Short Talk(s) Chosen from Abstracts
Poster Setup
11:45–1:00 PM
On Own for Lunch
11:45–5:00 PM
Poster Viewing
1:00–10:00 PM
Coffee Available
4:30–5:00 PM
Unraveling the Molecular Machinery of the Nephron in Function and Failure
5:00–7:00 PM
Laura Barisoni †, Duke University
Tissue is the Issue: AI Driven Image Analysis Maps Structural and Molecular Disease Trajectories
Katalin Susztak †, University of Pennsylvania
Defining Kidney Fibrosis. From Cellular Insight to Targeted Therapies
Olga G. Troyanskaya, Princeton University
Genes and Environment Driving CKD: Linking Environmental Exposures with Genetic Risk Assessment to Guide CKD Management
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Tuesday, April 14, 2026
Breakfast
7:30–8:30 AM
Poster Setup
8:00–8:30 AM
Poster Viewing
8:15–5:00 PM
CKD in Obesity and Diabetes: Driving the Disease Burden in the Cardio Metabolic Pandemic
8:30–11:30 AM
Tamer Coskun †, Eli Lilly & Company
Obesity Driven Metabolic Reprogramming: From Metabolic Profiling to Drug Targets for Cardiorenal Disease
Sepiso Masenga †, Mulungushi University
The Cardiovascular Metabolic Syndrome, Mechanism and Burden of Oxidative Stress in Vascular Renal Disease
Bei B. Zhang †, Novo Nordisk
Retuning the Incretin System and its Impact on Kidney Physiology and Cellular Function in DKD
Katherine R. Tuttle †, University of Washington
Finally Breaking the Death Spiral of CKD: Mechanistic Trials Defining the Mode of Action of the Incretin System
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Lunch
11:30–12:30 PM
Posters
12:00–2:30 PM
Coffee Available
4:30–5:00 PM
Primary Glomerular Diseases Driving CKD: Insight into a Rapidly Evolving Targeted Therapy Landscape
5:00–7:00 PM
Brad H. Rovin †, Ohio State University College of Medicine
Innate Immunity Modulation in Lupus Nephritis, Bringing Insight from Trials Back to the Bench
Chee Kay Cheung †, University of Leicester
The Right Drug for the Right IgAN in 2025: Impact of Endothelin Blockade on Glomerular Manifestations of IgA Nephritis
Tobias B. Huber †, University Medical Center Hamburg-Eppendorf
Understanding Filtration Barrier Failure Drives Novel Treatments in Nephrotic Syndrome
Short Talk(s) Chosen from Abstracts
On Own for Dinner
7:00–8:00 PM
Wednesday, April 15, 2026
Breakfast
7:30–8:30 AM
Genes and Kidney; Unique Opportunities for Targeted Therapies, Lessons Learned from ApoL1 and Beyond
8:30–11:30 AM
Whitney Besse †, Yale School of Medicine
Polycystic Kidney Disease: The Journey from Gene to Therapies
Martin Pollak †, Beth Israel Deaconess Medical Center
ApoL1 Biology and Kidney Disease
Akinlolu Ojo †, University of Kansa
ApoL1 across Continents: Lessons Learned on Gene Environment Interaction in H3 Africa KDRN
Glenn Chertow †, Stanford University
Lessons Learned from the First Trials Targeting ApoL1 Kidney Disease
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
On Own for Lunch
11:30–5:00 PM
Coffee Available
4:30–5:00 PM
Precision Clinical Trial Strategies for Kidney Disease
5:00–6:45 PM
Matthias Kretzler, University of Michigan
Lessons Learned from Matching Patients Renal Pathobiology to Targeted Therapies in Glomerular Disease
Maria Chiara Magnone, Janssen Inc.
Platform Trials in CKD, State of the Art in 2026
Hiddo Lambers Heerspink, University Medical Center Groningen
Precision Medicine Trials in CKD: Bringing Molecular Understanding of CKD Drugs to Clinical Care
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Social Hour with Lite Bites
7:00–8:00 PM
Cash Bar
8:00–11:00 PM
Entertainment
8:00–11:00 PM
Thursday, April 16, 2026
Departure
12:00–11:59 PM

Subscribe for Updates